An urgent clinical need exists to improve the survival of patients with pancreatic cancer through biomarker-driven therapeutic strategies. Such approaches include the targeting of metastatic pancreatic cancer that harbours germline BRCA mutations with poly(ADP-ribose) polymerase inhibitors as maintenance therapy following platinum-based chemotherapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis
BMC Cancer Open Access 29 August 2023
-
Molecular mechanisms of tumor resistance to radiotherapy
Molecular Cancer Open Access 15 June 2023
-
BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
Scientific Reports Open Access 26 February 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Miller, K. D. et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J. Clin. https://doi.org/10.3322/caac.21565 (2019).
Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).
Von Hoff, D. D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691–1703 (2013).
Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185–203 (2017).
Pilie, P. G. et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Clin. Oncol. 16, 181–104 (2018).
Golan, T. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1903387 (2019).
Gyawali, B. & Prasad, V. Combining drugs and extending treatment — a PFS end point is not sufficient. Nat. Rev. Clin. Oncol. 14, 521–522 (2017).
Dahan, L. et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: a randomized phase II trial (PRODIGE 35–PANOPTIMOX) [abstract]. J. Clin. Oncol. 36 (Suppl. 15), 4000 (2018).
Hu, C. et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA 319, 2401–2409 (2018).
Seeber, A. et al. Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression [abstract]. J. Clin. Oncol. 37 (Suppl. 15), 4133 (2019).
Hastak, K. et al. Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers. Oncotarget 8, 26344–26355 (2017).
Tempero, M. A. NCCN guidelines updates: pancreatic cancer. J. Natl Compr. Canc. Netw. 17, 603–605 (2019).
Stoffel, E. M. et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. J. Clin. Oncol. 37, 153–164 (2019).
Acknowledgements
The University of Texas MD Anderson Cancer Center is supported by the NIH Cancer Center Support Grant CA016672. This funding source had no input into study design and conduct; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.P. has received research support from Arqule, Bristol-Myers Squibb, Eli Lilly, Five Prime Therapeutics, GlaxoSmithKline. Mirati Therapeutics, Novartis,Onco Response, Red Hill Biopharma, Rgenix, Sanofi–Aventis, Sanofi US Services and Xencor, and has received consultancy fees or Speakers Bureau from 4D Pharma and Tyme. A.M. has received royalties from Cosmos Wisdom Biotechnology for a biomarker assay related to early detection of pancreatic cancer. T.A.Y. received research support from AstraZeneca, Bayer, Constellation, Eli Lilly, Jounce, Kyowa, Pfizer, Seattle Genetics, Tesaro and Vertex Pharmaceuticals, and has been a consultant for Aduro, Almac, AstraZeneca, Atrin, Bayer, Bristol-Myers Squibb, Calithera, Clovis, Cybrexa, EMD Serono, Ignyta, Jansen, Merck, Pfizer, Roche, Seattle Genetics and Vertex Pharmaceuticals
Rights and permissions
About this article
Cite this article
Pant, S., Maitra, A. & Yap, T.A. PARP inhibition — opportunities in pancreatic cancer. Nat Rev Clin Oncol 16, 595–596 (2019). https://doi.org/10.1038/s41571-019-0257-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0257-6
This article is cited by
-
BRCA genes as candidates for colorectal cancer genetic testing panel: systematic review and meta-analysis
BMC Cancer (2023)
-
Molecular mechanisms of tumor resistance to radiotherapy
Molecular Cancer (2023)
-
BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
Scientific Reports (2021)
-
Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials
Journal of Cancer Research and Clinical Oncology (2020)